Last updated: July 24, 2026
Executive summary
- Phendimetrazine tartrate is an established, older appetite suppressant with limited high-value patent upside versus next-generation weight-loss franchises, driven by short remaining commercial runway and high generic substitution likelihood.
- The most investable diligence focus is regulatory listing status (Orange Book and labeling), current NDA/ANDA holder(s), and any remaining formulation or method-of-use patents that could delay generic entry.
- Commercial upside is most exposed to supply continuity, controlled-substance distribution constraints, payer tightening on older agents, and competitive dynamics vs GLP-1 and dual agonists.
What is phendimetrazine tartrate and why does it matter for investors?
Quick take
Phendimetrazine tartrate is a sympathomimetic amine used for weight management as a short-term adjunct in selected patients. Investor-relevant features are not clinical novelty, but rather regulatory durability, ongoing FDA compliance burden, and defensibility of the product listing (NDA exclusivity, patent-protected label and formulations, and any REMS or controlled-substance constraints).
What drug category does phendimetrazine tartrate sit in?
- Therapeutic area: weight management (short-term adjunct to diet/exercise).
- Pharmacology: stimulant-like anorexigenic effect through noradrenergic pathways.
- Competitive pressure: dominated commercially by newer anti-obesity medicines (GLP-1/GIP and related mechanisms), which shifts payer and prescriber preferences.
What revenue model does an older obesity agent typically follow?
- Lower pricing power and higher sensitivity to:
- generic price compression
- formularies
- quantity limits
- availability and manufacturing scale
- If the product is widely genericized, the investment case relies on:
- market share retention through contracts
- supply assurance
- compliance and pharmacovigilance execution
- any niche remaining exclusivities that delay generic entry for a specific strength/form
What patents protect phendimetrazine tartrate in the US?
Quick take
An investment-quality view requires the exact Orange Book patent estate tied to the specific NDA/strength/dosage form for phendimetrazine tartrate. Without the Orange Book listing record and patent identifiers, an accurate “how many patents” and “which claims” count cannot be produced.
Where investors usually find the enforceable estate
- FDA Orange Book: listed patents that cover:
- active ingredient
- drug product formulation
- method-of-use claims
- manufacturing process claims (when listed)
- Litigation records: PTAB challenges, Hatch-Waxman litigations, and settlement agreements.
How to map “what is protected” to value
- If only composition of matter patents existed, they are typically long expired for a mature molecule.
- Remaining value usually comes from:
- formulation patents for specific tablet/capsule strength or excipient system
- method-of-use restrictions tied to label language
- manufacturing process patents affecting bioavailability or stability
- combination products (if applicable)
- The value impact is decisive: the weaker the listing estate, the more generic entry risk dominates the forecast.
When does phendimetrazine tartrate lose exclusivity in the US?
Quick take
Exclusivity timing must be anchored to the specific FDA approval date(s) and whether the product benefits from:
- NDA exclusivity periods
- pediatric exclusivity extensions
- 80/180/365 exclusivity for qualifying supplements (as applicable)
Without the NDA/approval history and exclusivity codes for phendimetrazine tartrate, a definitive exclusivity calendar cannot be provided.
What usually drives exclusivity for older obesity drugs
- Older approvals often have:
- expired regulatory exclusivity
- minimal patent-backed delays
- If a late-life formulation or label change occurred, the only meaningful delay can be:
- a new listing tied to a supplement with exclusivity
- or an added patent that is still enforceable
What generic entry risks exist for phendimetrazine tartrate?
Quick take
Generic entry risk for established stimulant obesity agents is typically high unless:
- Orange Book lists still-enforceable patents, or
- there is an unusually narrow remaining protected attribute (formulation or method-of-use).
Paragraph IV risk: what to look for
An investment-grade “generic launch risk” assessment relies on:
- ANDA filings with Paragraph IV certifications referencing specific Orange Book patents
- notice letters and litigation outcomes
- court outcomes or settlements tied to agreed launch dates
Practical risk drivers
- Unit economics: genericized markets compress margins quickly.
- Supply chain: shortages or production scale failures can cause temporary premium pricing, but this is operational risk, not IP protection.
- Regulatory: controlled-substance handling and distribution compliance can affect fill rates.
What is the Orange Book status of phendimetrazine tartrate?
Quick take
Orange Book status must be verified by NDA number, dosage form, and strength to list:
- which patents are currently active in the listing
- patent expiration dates
- patent use codes (drug substance, drug product, method-of-use, or manufacturing)
A complete Orange Book-derived status summary cannot be produced without the Orange Book listing details for phendimetrazine tartrate.
What to extract from Orange Book for diligence
For each listed patent:
- patent number
- title
- assignee
- listing use code(s)
- listed expiration date
- whether the patent is expected to expire soon versus still enforceable for years
How strong is the patent estate for phendimetrazine tartrate?
Quick take
A strength rating must be claim-specific (composition vs formulation vs method-of-use) and time-specific (remaining life). Without enumerated patents and their legal status, strength cannot be scored accurately.
Typical strength patterns for older small-molecule obesity drugs
- Composition of matter: usually expired.
- Formulation/process: sometimes the only remaining defensibility, but often limited.
- Method-of-use: label-driven; may narrow generic freedom only if claims are tied to enforceable label elements and have clear infringement hooks.
Litigation and PTAB: the value-discount mechanics
Even if patents are listed:
- an active PTAB reexamination or post-grant review can quickly reduce enforceability
- a favorable court construction can narrow scope
- settlements can cap future entry but often at low strategic value unless launch is materially delayed
What patent litigation affects phendimetrazine tartrate?
Quick take
Patent litigation affects the entry timing and risk profile only if it involves:
- Paragraph IV ANDA challenges to Orange Book patents, or
- enforcement suits by the brand holder.
A litigation status summary cannot be produced without identified cases, dockets, and case outcomes for phendimetrazine tartrate.
What investors must verify in litigation dockets
- case number and court
- asserted patents and claim construction results
- settlement terms: agreed launch date, stipulations, and “carve-outs”
- any consent judgments affecting future generic filings
What formulations are protected by phendimetrazine tartrate patents?
Quick take
Formulation-level protection must be tied to the specific dosage form and strength appearing in the FDA listing (for example, immediate-release tablets at specific mg). Without that linkage, the protected-formulation landscape cannot be stated.
Formulation diligence checklist
- excipient and coating systems (if protected)
- dissolution profile targets
- stability and shelf-life extensions
- bioequivalence and reference product reliance issues for ANDA filers
How does phendimetrazine tartrate compare with other anti-obesity drugs for investment exposure?
Quick take
The investment profile is materially different from GLP-1 and dual agonists:
- phendimetrazine tartrate is a mature, likely genericized, controlled-substance-adjacent product
- GLP-1 franchise drugs have long patent runways and patent-protected biologic/drug-device ecosystems
- the key investor exposure for phendimetrazine tartrate is competitive erosion and regulatory listing details, not blockbuster innovation
Competitive landscape: what changes outcomes
- formulary access trends
- payer restrictions on older agents versus modern therapies
- prescriber shift toward newer mechanisms
- volume volatility in small molecule obesity segments
What is the FDA regulatory status and labeling risk for phendimetrazine tartrate?
Quick take
FDA status diligence hinges on:
- NDA/ANDA reference relationships
- current prescribing information
- REMS or risk management requirements (if any)
- controlled-substance scheduling and compliance burdens
A labeling-risk analysis cannot be completed without the current FDA label and the product’s regulatory designation.
Label-driven risk vectors
- warnings and contraindications affecting eligible patient pools
- dose limitations impacting sales volume
- safety communications that alter prescribing behavior
Which companies are most exposed to phendimetrazine tartrate pricing and supply?
Quick take
Company exposure depends on:
- which firm holds the active NDA and marketing authorization
- the number of generic manufacturers distributing the product
- current market share and contract pricing
A company-level exposure ranking requires up-to-date dataset linkage to NDA/ANDA holders and market sales data for phendimetrazine tartrate, which is not available here.
What manufacturing and IP barriers exist for phendimetrazine tartrate generics?
Quick take
For small-molecule generics, manufacturing barriers typically center on:
- bioequivalence and dissolution targets
- scale-up consistency
- quality system compliance
- any remaining formulation patents that block certain excipient or process choices
Without the patent list and any remaining enforceable constraints, the barrier assessment cannot be stated.
What licensing opportunities exist for phendimetrazine tartrate?
Quick take
Licensing attractiveness is tied to:
- exclusivity blocks (patents still in force)
- unique formulation/process or differentiated product attributes
- remaining life on any protected method-of-use claims
Without identifiable active patents and their remaining term, the licensing landscape cannot be quantified.
Investment scenario: base case, downside, and upside
Quick take
A defensible scenario model for phendimetrazine tartrate must reflect whether the product is:
- effectively brand-protected (rare in mature molecules)
- partially protected (specific dosage forms or methods of use)
- fully genericized (market share and margin driven by supply and contracting)
Without Orange Book and litigation specifics, only conditional statements are possible.
Base case (most consistent with mature small molecule)
- Market share pressure from generics and payer scrutiny.
- Profit pool driven by manufacturing efficiency and contract access, not IP.
- IP upside minimal unless an active, unexpired formulation/method-of-use patent is identified.
Downside case
- Accelerated generic penetration and price compression.
- Supply disruptions that force backorders and reduce revenue continuity.
- Label restrictions or safety communications that lower demand.
Upside case
- Any remaining active patents tied to a differentiated strength/formulation block certain generic entrants.
- Contract wins with wholesalers or pharmacy chains.
- Temporary price recovery from supply constraints.
Key Takeaways
- Phendimetrazine tartrate’s investment value is primarily a function of remaining FDA listing and patent enforceability, not new clinical differentiation.
- The decisive diligence items are Orange Book patent inventory (by NDA/strength), exact expiration dates, and any active Paragraph IV litigation or settlements.
- In mature small-molecule obesity segments, absent enforceable late-life patents, generic entry risk dominates and commercial returns rely on execution: quality, supply continuity, and payer contracting.
FAQs
- Is phendimetrazine tartrate currently protected by active Orange Book patents?
- What are the most likely patent types still affecting generic entry for older obesity small molecules?
- How do Paragraph IV certifications change the projected generic launch timeline for phendimetrazine tartrate?
- What labeling changes typically shift demand for stimulant-based weight loss agents?
- How should investors model price compression in mature generic anti-obesity markets?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-24).
- FDA. Drug Approval Reports and labeling records for phendimetrazine tartrate (NDA/ANDA). (Accessed 2026-07-24).
